<unk>  (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS).<unk>  works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells. In March 2018, it was voluntarily withdrawn from the market by Biogen and Abbvie after reports of autoimmune encephalitis in Europe.
Daclizumab
Tocilizumab
Brolucizumab
Satralizumab
Ravulizumab
Reslizumab
Natalizumab
Benralizumab